A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Abstract Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to i...

Full description

Bibliographic Details
Main Authors: Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Format: Article
Language:English
Published: BMJ Publishing Group 2018-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
High-dose interleukin-2
Vemurafenib
BRAF-mutated metastatic melanoma
Multicenter
Phase II
Online Access:http://link.springer.com/article/10.1186/s40425-018-0387-x

Internet

http://link.springer.com/article/10.1186/s40425-018-0387-x

Similar Items